Key result
Nesiritide may increase 30-day mortality compared with noninotrope-based control therapy in acutely decompensated heart failure (7.2% vs 4.0%; RR 1.74; 95% CI 0.97-3.12; P=0.059).
Why the study?
Does nesiritide increase 30-day mortality compared to noninotrope-based control therapies in patients with acutely decompensated heart failure?
Population
862 patients with acutely decompensated heart failure from 3 randomized double-blind trials
Comparison
Nesiritide administered as a single infusion vs Noninotrope-based control therapies, primarily…
Design
Meta-analysis, randomized, double-blind
Follow-up
30 days
Authors
Loading...
Possible mortality increase warrants caution with nesiritide in acute decompensated HF; challenges safety assumptions and leaves risk unresolved.
Meta-Analysis (n=862)
Double-blind
Does nesiritide increase 30-day mortality compared to noninotrope-based control therapies in patients with acutely decompensated heart failure?
Effect estimate: RR 1.74 (95% CI 0.97-3.12)
Absolute Event Rate: 7.2% vs 4%
p-value: p=0.059
Nesiritide may be associated with an increased short-term risk of death compared with noninotrope-based control therapy in patients with acutely decompensated heart failure.
Sackner‐Bernstein et al. (2005) conducted a meta-analysis in Acutely decompensated heart failure (n=862). Nesiritide vs. Noninotrope-based control therapies was evaluated on Death within 30 days (RR 1.74, 95% CI 0.97-3.12, p=0.059). Nesiritide may increase 30-day mortality compared with noninotrope-based control therapy in acutely decompensated heart failure (7.2% vs 4.0%; RR 1.74; 95% CI 0.97-3.12; P=0.059).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: